FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL							
	OMB Number: 3235-028 Estimated average burden							
	hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kulkarni Samarth</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ]					(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner						
(Last)	`	rst) APEUTICS	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/13/2023						X Officer (give title Other (specify below)  Chief Executive Officer					
105 WEST FIRST STREET				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	N M	A	02127										led by More	•	ting Person One Report	
(City) (State) (Zip)				R	Rule 10b5-1(c) Transaction Indication											
								icate that a trar defense condi					n or written p	olan that	t is intended	to
		Tab	le I - Non-D	erivativ	e Se	curities	s Ac	quired, Di	isposed	of, or Be	neficiall	y Owned				
Date			Transaction te onth/Day/Y	Execution Date,		, Transaction Disposed ( Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an		5. Amour Securitie Beneficia Owned F Reported	es Fo ally (D Following (I)	Form:	Direct Condinect Etr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code V	Amoun	(A) o	Price	Transact (Instr. 3 a	ion(s)			mod. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Yea		3A. Deemed Execution Date, if any (Month/Day/Yea	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly [	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$44.31	10/13/2023		A		52,500		(1)	10/13/2033	Common Shares	52,500	\$0.00	52,500		D	
Restricted Stock Unit	(2)	10/13/2023		A		25,000		(3)	(3)	Common Shares	25,000	\$0.00	25,000		D	

## Explanation of Responses:

- 1. This option was granted on October 13, 2023 with respect to 52,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
- 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- 3. This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.

/s/ Elizabeth Ryland Waldinger, attorney-in-fact

10/17/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.